BIOL.Q Stock Overview
Develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
BIOLASE, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0099 |
| 52 Week High | US$0.26 |
| 52 Week Low | US$0.004 |
| Beta | 0.69 |
| 1 Month Change | 11.24% |
| 3 Month Change | 98.00% |
| 1 Year Change | -93.39% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Biolase partners with dental speciality programs across U.S.
Aug 31BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity
Jul 21BIOLASE amends senior secured term loan with SWK Funding
Jul 01BIOLASE: Bad News Across The Board - Sell
Mar 21Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?
Feb 24
BIOLASE - Speculative Buy After Strong Preliminary Q4 Results
Jan 11BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors
Nov 24Shareholder Returns
| BIOL.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.5% | -0.3% | 0.8% |
| 1Y | -93.4% | 12.9% | 22.4% |
Return vs Industry: BIOL.Q underperformed the US Medical Equipment industry which returned 12.9% over the past year.
Return vs Market: BIOL.Q underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| BIOL.Q volatility | |
|---|---|
| BIOL.Q Average Weekly Movement | 35.1% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOL.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BIOL.Q's weekly volatility (35%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 157 | John Beaver | www.biolase.com |
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production.
BIOLASE, Inc. Fundamentals Summary
| BIOL.Q fundamental statistics | |
|---|---|
| Market cap | US$362.31k |
| Earnings (TTM) | -US$15.97m |
| Revenue (TTM) | US$46.03m |
0.0x
P/S Ratio0.0x
P/E RatioIs BIOL.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOL.Q income statement (TTM) | |
|---|---|
| Revenue | US$46.03m |
| Cost of Revenue | US$30.18m |
| Gross Profit | US$15.85m |
| Other Expenses | US$31.82m |
| Earnings | -US$15.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 34.44% |
| Net Profit Margin | -34.69% |
| Debt/Equity Ratio | -486.1% |
How did BIOL.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/18 22:00 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BIOLASE, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Bruce Jackson | Benchmark Company |
| Kyle Bauser | Colliers Securities |